A new financing technique may reduce the risk associated with investing in the treatment of new diseases and potentially unlock new levels of funding for developing so-called “orphan” drugs.

Studying this issue against the backdrop of the apparent lack of risk aversion that led to the recent financial crisis, MIT Sloan Prof. Andrew Lo has developed an evolutionary model of behavior.